VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.

In this study, two hexapeptides of IPPVPP and VPPIPP were innovated by using two commercial antihypertensive peptides IPP and VPP as two domains cis-linked and trans-linked, respectively. The IPPVPP and VPPIPP were chemically synthesized and evaluated for the antihypertensive activity in vitro/vivo....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fengyun Ding, Bingjun Qian, Xin Zhao, Shanqi Shen, Yun Deng, Danfeng Wang, Feng Zhang, Zhongquan Sui, Pu Jing
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cbaf812779844977bdd1166618597d7d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cbaf812779844977bdd1166618597d7d
record_format	dspace
spelling	oai:doaj.org-article:cbaf812779844977bdd1166618597d7d2021-11-18T07:47:30ZVPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.1932-620310.1371/journal.pone.0062384https://doaj.org/article/cbaf812779844977bdd1166618597d7d2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23638059/?tool=EBIhttps://doaj.org/toc/1932-6203In this study, two hexapeptides of IPPVPP and VPPIPP were innovated by using two commercial antihypertensive peptides IPP and VPP as two domains cis-linked and trans-linked, respectively. The IPPVPP and VPPIPP were chemically synthesized and evaluated for the antihypertensive activity in vitro/vivo. The in vitro ACE-inhibitory study showed that VPPIPP (34.71 ± 4.38%) has a significantly stronger activity than that of IPPVPP (13.17 ± 0.25%) at a treatment concentration of 10 µmol/L, but it was weaker than the commercial IPP (56.97 ± 2.40%) (P<0.05). However, VPPIPP, IPPVPP, and IPP lowered the systolic blood pressure by 21 ± 0.9%, 17.4 ± 1.3% and 17.5 ± 0.9%, respectively, in rats at 1.5 mg/kg body weight dosage. The result was consistent with the mRNA level of sarcoplasmic reticulum Ca(2+), Mg(2+) -ATPase Gene (SERCA 2a) in rat hearts. Additionally, VPPIPP and IPPVPP showed no negative impact on blood glycometabolism. The results suggested that the two hexapeptides could be potent bioactive peptides in functional foods for people with high blood pressure.Fengyun DingBingjun QianXin ZhaoShanqi ShenYun DengDanfeng WangFeng ZhangZhongquan SuiPu JingPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 4, p e62384 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Fengyun Ding Bingjun Qian Xin Zhao Shanqi Shen Yun Deng Danfeng Wang Feng Zhang Zhongquan Sui Pu Jing VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.
description	In this study, two hexapeptides of IPPVPP and VPPIPP were innovated by using two commercial antihypertensive peptides IPP and VPP as two domains cis-linked and trans-linked, respectively. The IPPVPP and VPPIPP were chemically synthesized and evaluated for the antihypertensive activity in vitro/vivo. The in vitro ACE-inhibitory study showed that VPPIPP (34.71 ± 4.38%) has a significantly stronger activity than that of IPPVPP (13.17 ± 0.25%) at a treatment concentration of 10 µmol/L, but it was weaker than the commercial IPP (56.97 ± 2.40%) (P<0.05). However, VPPIPP, IPPVPP, and IPP lowered the systolic blood pressure by 21 ± 0.9%, 17.4 ± 1.3% and 17.5 ± 0.9%, respectively, in rats at 1.5 mg/kg body weight dosage. The result was consistent with the mRNA level of sarcoplasmic reticulum Ca(2+), Mg(2+) -ATPase Gene (SERCA 2a) in rat hearts. Additionally, VPPIPP and IPPVPP showed no negative impact on blood glycometabolism. The results suggested that the two hexapeptides could be potent bioactive peptides in functional foods for people with high blood pressure.
format	article
author	Fengyun Ding Bingjun Qian Xin Zhao Shanqi Shen Yun Deng Danfeng Wang Feng Zhang Zhongquan Sui Pu Jing
author_facet	Fengyun Ding Bingjun Qian Xin Zhao Shanqi Shen Yun Deng Danfeng Wang Feng Zhang Zhongquan Sui Pu Jing
author_sort	Fengyun Ding
title	VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.
title_short	VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.
title_full	VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.
title_fullStr	VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.
title_full_unstemmed	VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.
title_sort	vppipp and ippvpp: two hexapeptides innovated to exert antihypertensive activity.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/cbaf812779844977bdd1166618597d7d
work_keys_str_mv	AT fengyunding vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT bingjunqian vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT xinzhao vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT shanqishen vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT yundeng vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT danfengwang vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT fengzhang vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT zhongquansui vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity AT pujing vppippandippvpptwohexapeptidesinnovatedtoexertantihypertensiveactivity
_version_	1718423001274253312

VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.

Ejemplares similares